These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8369164)

  • 21. Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody.
    Hou W; Fang C; Liu J; Yu H; Qi J; Zhang Z; Yuan R; Xiong D; Gao S; Adam Yuan Y; Li S; Gu Y; Xia N
    Antiviral Res; 2015 Oct; 122():101-11. PubMed ID: 26259811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in affinity of anti-CD4 monoclonal antibodies predict their effects on syncytium induction by human immunodeficiency virus.
    Wilks D; Walker L; O'Brien J; Habeshaw J; Dalgleish A
    Immunology; 1990 Sep; 71(1):10-5. PubMed ID: 2210798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lateral diffusion of CD4 on the surface of a human neoplastic T-cell line probed with a fluorescent derivative of the envelope glycoprotein (gp120) of human immunodeficiency virus type 1 (HIV-1).
    Pal R; Nair BC; Hoke GM; Sarngadharan MG; Edidin M
    J Cell Physiol; 1991 May; 147(2):326-32. PubMed ID: 2040664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.
    Moore JP; Sattentau QJ; Clapham PR
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1273-9. PubMed ID: 2078408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.
    Mulligan MJ; Ritter GD; Chaikin MA; Yamshchikov GV; Kumar P; Hahn BH; Sweet RW; Compans RW
    Virology; 1992 Mar; 187(1):233-41. PubMed ID: 1736526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4 activation of HIV fusion.
    Sattentau QJ
    Int J Cell Cloning; 1992 Nov; 10(6):323-32. PubMed ID: 1281202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational perturbation of the envelope glycoprotein gp120 of human immunodeficiency virus type 1 by soluble CD4 and the lectin succinyl Con A.
    Pal R; DeVico A; Rittenhouse S; Sarngadharan MG
    Virology; 1993 Jun; 194(2):833-7. PubMed ID: 8503188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity.
    Kennedy MS; Orloff S; Ibegbu CC; Odell CD; Maddon PJ; McDougal JS
    AIDS Res Hum Retroviruses; 1991 Dec; 7(12):975-81. PubMed ID: 1687500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies.
    Arthos J; Cicala C; Steenbeke TD; Chun TW; Dela Cruz C; Hanback DB; Khazanie P; Nam D; Schuck P; Selig SM; Van Ryk D; Chaikin MA; Fauci AS
    J Biol Chem; 2002 Mar; 277(13):11456-64. PubMed ID: 11805109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
    Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
    Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1.
    Esser U; Speck RF; Deen KC; Atchison RE; Sweet R; Goldsmith MA
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1845-54. PubMed ID: 11118070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-tropic HIV in monocytes and T cells.
    Gomatos PJ; Stamatos NM; Gendelman HE; Fowler A; Hoover DL; Kalter DC; Burke DS; Tramont EC; Meltzer MS
    J Immunol; 1990 Jun; 144(11):4183-8. PubMed ID: 2341717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?
    Clements GJ; Price-Jones MJ; Stephens PE; Sutton C; Schulz TF; Clapham PR; McKeating JA; McClure MO; Thomson S; Marsh M
    AIDS Res Hum Retroviruses; 1991 Jan; 7(1):3-16. PubMed ID: 2015114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry.
    Corbeau P; Benkirane M; Weil R; David C; Emiliani S; Olive D; Mawas C; Serre A; Devaux C
    J Immunol; 1993 Jan; 150(1):290-301. PubMed ID: 7678031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG).
    Flasher D; Konopka K; Chamow SM; Dazin P; Ashkenazi A; Pretzer E; Düzgünes N
    Biochim Biophys Acta; 1994 Aug; 1194(1):185-96. PubMed ID: 8075135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of CD4-gp120 activation intermediates during human immunodeficiency virus type 1 syncytium formation.
    Hart TK; Truneh A; Bugelski PJ
    AIDS Res Hum Retroviruses; 1996 Sep; 12(14):1305-13. PubMed ID: 8891109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.
    Orloff SL; Kennedy MS; Belperron AA; Maddon PJ; McDougal JS
    J Virol; 1993 Mar; 67(3):1461-71. PubMed ID: 8437224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.
    Gauduin MC; Allaway GP; Maddon PJ; Barbas CF; Burton DR; Koup RA
    J Virol; 1996 Apr; 70(4):2586-92. PubMed ID: 8642690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.